Therefore, we believe the data of the Alecardio trial to be of importance as it gives the opportunity to evaluate possible beneficial effects of PPAR-α/γ agonists on NAFLD and associated fibrosis in a large number of patients. This evidence concerns the gene PPARA and fibrosis.